ASP Isotopes (NASDAQ:ASPI) Trading Up 8.9% – Still a Buy?

ASP Isotopes Inc. (NASDAQ:ASPI)’s stock price was up 8.9% during trading on Friday . The stock traded as high as $6.84 and last traded at $6.7830. Approximately 1,514,542 shares traded hands during trading, a decline of 71% from the average daily volume of 5,216,768 shares. The stock had previously closed at $6.23.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on ASPI shares. Canaccord Genuity Group reaffirmed a “buy” rating and set a $11.00 price objective on shares of ASP Isotopes in a research note on Tuesday, April 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of ASP Isotopes in a research note on Friday, March 27th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $13.00.

ASP Isotopes Trading Up 5.1%

The company has a debt-to-equity ratio of 0.69, a quick ratio of 4.37 and a current ratio of 4.39. The firm has a market cap of $824.65 million, a PE ratio of -3.15 and a beta of 3.42. The stock’s 50 day simple moving average is $5.74 and its 200 day simple moving average is $5.85.

ASP Isotopes (NASDAQ:ASPI) last released its quarterly earnings results on Wednesday, May 20th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.06. ASP Isotopes had a negative net margin of 644.40% and a negative return on equity of 112.46%. The business had revenue of $8.36 million during the quarter, compared to analysts’ expectations of $3.68 million.

Insider Activity at ASP Isotopes

In other ASP Isotopes news, CEO Paul Elliot Mann sold 83,759 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $7.76, for a total value of $649,969.84. Following the completion of the transaction, the chief executive officer owned 9,579,845 shares of the company’s stock, valued at $74,339,597.20. The trade was a 0.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Heather Kiessling sold 23,124 shares of the business’s stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $5.48, for a total transaction of $126,719.52. Following the completion of the transaction, the chief financial officer directly owned 709,376 shares of the company’s stock, valued at approximately $3,887,380.48. This represents a 3.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 233,221 shares of company stock worth $1,707,989 in the last 90 days. 14.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On ASP Isotopes

A number of institutional investors have recently made changes to their positions in ASPI. Encompass Capital Advisors LLC purchased a new stake in shares of ASP Isotopes in the 1st quarter valued at $30,551,000. Alyeska Investment Group L.P. boosted its stake in shares of ASP Isotopes by 73.4% in the 4th quarter. Alyeska Investment Group L.P. now owns 4,895,546 shares of the company’s stock valued at $26,191,000 after purchasing an additional 2,072,851 shares in the last quarter. UBS Group AG boosted its stake in shares of ASP Isotopes by 150.3% in the 4th quarter. UBS Group AG now owns 2,406,457 shares of the company’s stock valued at $12,875,000 after purchasing an additional 1,445,165 shares in the last quarter. Marshall Wace LLP boosted its stake in shares of ASP Isotopes by 3,669.1% in the 3rd quarter. Marshall Wace LLP now owns 1,279,121 shares of the company’s stock valued at $12,305,000 after purchasing an additional 1,245,184 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of ASP Isotopes by 37.9% in the 3rd quarter. Vanguard Group Inc. now owns 4,516,763 shares of the company’s stock valued at $43,451,000 after purchasing an additional 1,241,024 shares in the last quarter. Hedge funds and other institutional investors own 16.80% of the company’s stock.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.